FAERS Eptifibatide Adverse Event Reports Analyzed with Disproportionality Methods

Peng Zhang's study analyzes adverse event reports for the drug Eptifibatide from the FDA Adverse Event Reporting System (FAERS) since 2004. The research uses multiple disproportionality analysis methods, including BCPNN, MGPS, PRR, and ROR, to evaluate real-world safety. The dataset, last updated in March 2026, is a 76.8 KB document containing the study's results table.

Use Cases

• Validate known adverse drug reactions like bleeding and thrombocytopenia based on the disproportionality analysis results.
• Identify potential new safety signals such as acute myocardial infarction or hemorrhagic pancreatitis based on the study's findings.
• Compare signal detection performance across different disproportionality methods (BCPNN, MGPS, PRR, ROR) based on the described methodology.
• Support clinical decision-making for Eptifitate use in ARDS treatment based on the aggregated real-world safety evidence.

Strengths

• Analysis uses multiple established disproportionality methods (BCPNN, MGPS, PRR, ROR) for signal detection.
• Data source is the FDA Adverse Event Reporting System (FAERS), a major pharmacovigilance database.
• Study timeframe covers reports since 2004, providing a long-term safety perspective.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is a 76.8 KB DOCX file, suggesting it contains summary results rather than the raw underlying FAERS data.
• Description metadata is limited; actual data structure and quality require manual inspection after download.

Provenance

Source

FDA Adverse Event Reporting System (FAERS)

Collection Method

Disproportionality analysis of spontaneous adverse event reports where Eptifibatide was the primary suspected drug.

Time Range

Reports from 2004 onward

Freshness

Last updated 2026-03-18 07:38:19

Geography

Global (FAERS data)